@peterattiamd
2 posts audited · 11 claims analysed
Science evidence grade
Based on 11 claims across 2 audits
6
Supported
55%
2
Overstated
18%
0
Misleading
0%
3
No Evidence
27%
Share this evidence grade
Claim-level evidence grades — not a character judgment. Methodology · Right of reply · Leaderboards
What @peterattiamd claims actually are
We separate claims into three buckets: backed by evidence, factually incorrect, and grey — like animal-only findings sold as human fact (e.g. BPC-157 “fixes Achilles” from rat studies).
Evidence-based
55%
6 claims
Claims that align with published human or clinical evidence at the stated strength.
Ex: “Semaglutide can reduce body weight in adults with obesity” — supported by large RCTs.
Factually incorrect
0%
0 claims
Claims that conflict with the evidence, invent certainty, or omit critical safety/context in a misleading way.
Ex: “Peptides have no side effects” — contradicts known adverse-event profiles.
Grey / overstated
45%
5 claims
Plausible direction but wrong certainty — animal-only data sold as human fact, dose/effect overstated, or no adequate published support yet.
Ex: “BPC-157 fixes Achilles tears” — often rests on rodent tendon models, not proven human Achilles repair trials.
Evidence mix
Share of audited claims in each bucket
Verdict detail
Grey splits into overstated (wrong certainty) vs no published support
Claims over time
Stacked by bucket as audits land — plus the running evidence grade
Gold line = running science evidence grade (Supported + ½ Overstated ÷ total claims).
Audit history(2 posts)
“Why doesn't everyone with high LDL-C develop atherosclerosis? | Tom Dayspring, M.D. This clip is from episode # 395 of The Drive which was released on 6/8/26. In the full episode, we cover: - The brain's independent cholesterol system: why the organ with the most cholesterol in the body produces and manages its own supply almost entirely separate from circulating lipoproteins, and how astrocytes supply neurons through a dedicated internal transport system - APOE genotype and Alzheimer's disease risk: how the apoE4 isoform disrupts cholesterol delivery to neurons, why that disruption connects to amyloid and tau pathology, and what the non-linear risk increase across genotypes means in practice - Lipid-lowering therapies and the brain: what the evidence shows about statins, ezetimibe, and omega-3 fatty acids when it comes to cognition, neurodegeneration, and brain cholesterol metabolism - Obicetrapib and Alzheimer's disease risk: early data from the BROADWAY trial showing promising movement in - Alzheimer's biomarkers including p-tau, the mechanism by which CETP inhibition may increase apoA-I entry into the brain, and why the effect appears especially pronounced in APOE4 carriers - Much more Listen (Ep. # 395) to the full episode on my website or your favorite podcast player.”
Claims 1 and 2 regarding APOE4's role in cholesterol disruption and amyloid/tau pathology are well-supported by substantial peer-reviewed literature and represent established neurobiology. However, Claims 3, 4, and 5—which form the core of the post (obicetrapib efficacy for Alzheimer's, the proposed mechanism, and differential APOE4 effect)—lack any published clinical trial data, mechanistic studies, or peer-reviewed support. The BROADWAY trial is real but does not appear to test Alzheimer's biomarkers. The leap from APOE4 biology and CETP inhibition to a specific Alzheimer's benefit in APOE4 carriers is conceptually plausible but entirely unsupported by current literature.
“274 - Performance-enhancing drugs and hormones—risks, rewards, & broader implications for the public”
HGH's broad role in tissue growth and its direct lipolytic mechanism (FFA liberation) are well-supported by human clinical evidence. However, claims about prevention of age-related bone strength decline, fat-burning capacity preservation, bone mineral density enhancement, and connective tissue integrity lack specific human clinical validation. The evidence tier for most claims remains theoretical or preclinical; creators should distinguish between established mechanisms (tissue growth, lipolysis) and claims requiring further human clinical evidence (bone strength, metabolic aging, connective tissue).
Audit another post from @peterattiamd
Paste their social post link to add a new audit